RX-3117
Based on 2 publication(s) in Google Scholar
RX-3117 (TV-1360) is a potent and orally active anticancer and antimetaboliteagent. RX-3117 inhibits DNA methyltransferase 1 (DNMT1). RX-3117 shows antiproliferative and anti-tumour activity. RX-3117 induces cell cycle arrest at S phase and apoptosis.
For research use only. We do not sell to patients.
- Purity : 99.25%
- CAS No.: 865838-26-2
- Formula: C10H12FN3O4
- Molecular Weight:257.22
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) RX-3117
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.5 μM
Compound: 5a
|
Antitumor activity against human A549 cells by SRB method
Antitumor activity against human A549 cells by SRB method
|
[PMID: 22524616] |
| HCT-116 | IC50 |
0.19 μM
Compound: 5a
|
Antitumor activity against human HCT116 cells by SRB method
Antitumor activity against human HCT116 cells by SRB method
|
[PMID: 22524616] |
| HeLa | IC50 |
1.35 μM
Compound: 5a
|
Antitumor activity against human HeLa cells by SRB method
Antitumor activity against human HeLa cells by SRB method
|
[PMID: 22524616] |
| HepG2 | IC50 |
0.79 μM
Compound: 5a
|
Antitumor activity against human HepG2 cells by SRB method
Antitumor activity against human HepG2 cells by SRB method
|
[PMID: 22524616] |
| HT-29 | IC50 |
0.28 μM
Compound: 5a
|
Antitumor activity against human HT-29 cells by SRB method
Antitumor activity against human HT-29 cells by SRB method
|
[PMID: 22524616] |
| K562 | IC50 |
0.82 μM
Compound: 5a
|
Antitumor activity against human K562 cells by SRB method
Antitumor activity against human K562 cells by SRB method
|
[PMID: 22524616] |
| LNCaP | IC50 |
2.67 μM
Compound: 5a
|
Antitumor activity against human LNCAP cells by SRB method
Antitumor activity against human LNCAP cells by SRB method
|
[PMID: 22524616] |
| MCF7 | IC50 |
0.34 μM
Compound: 5a
|
Antitumor activity against human MCF7 cells by SRB method
Antitumor activity against human MCF7 cells by SRB method
|
[PMID: 22524616] |
| MDA-MB-231 | IC50 |
0.18 μM
Compound: 5a
|
Antitumor activity against human MDA-MB-231 cells by SRB method
Antitumor activity against human MDA-MB-231 cells by SRB method
|
[PMID: 22524616] |
| MKN-45 | IC50 |
0.34 μM
Compound: 5a
|
Antitumor activity against human MKN45 cells by SRB method
Antitumor activity against human MKN45 cells by SRB method
|
[PMID: 22524616] |
| NCI-H226 | IC50 |
0.25 μM
Compound: 5a
|
Antitumor activity against human NCI-H226 cells by SRB method
Antitumor activity against human NCI-H226 cells by SRB method
|
[PMID: 22524616] |
| OVCAR-3 | IC50 |
0.8 μM
Compound: 5a
|
Antitumor activity against human OVCAR3 cells by SRB method
Antitumor activity against human OVCAR3 cells by SRB method
|
[PMID: 22524616] |
| PANC-1 | IC50 |
0.62 μM
Compound: 5a
|
Antitumor activity against human PANC1 cells by SRB method
Antitumor activity against human PANC1 cells by SRB method
|
[PMID: 22524616] |
| PC-3 | IC50 |
0.63 μM
Compound: 5a
|
Antitumor activity against human PC3 cells by SRB method
Antitumor activity against human PC3 cells by SRB method
|
[PMID: 22524616] |
| SK-MEL-28 | IC50 |
1.38 μM
Compound: 5a
|
Antitumor activity against human SK-MEL-28 cells by SRB method
Antitumor activity against human SK-MEL-28 cells by SRB method
|
[PMID: 22524616] |
| U-251 | IC50 |
0.83 μM
Compound: 5a
|
Antitumor activity against human U251 cells by SRB method
Antitumor activity against human U251 cells by SRB method
|
[PMID: 22524616] |
In Vitro
RX-3117 causes both inhibition of DNA and RNA synthesis[1].
RX-3117 (11.7, 21 μM; 48 h) shows antiproliferative activity in A549, SW1573 cells[1].
RX-3117 is activated by uridine-cytidine kinase 2 (UCK2)[1].
RX-3117 (1-25 μM; 72 h) inhibits the growth of HCT-116, MDA-MB-231, PANC-1, Caki-1, MCF7, A549, MKN45, U251 cells with IC50s of 0.39, 0.18, 0.62, 0.84, 0.34, 0.34, 0.50, 0.83 μM, respectively[2].
RX-3117 (5, 10 μM; 4 days) induces cell cycle arrest at S phase and apoptosis[2].
RX-3117 (1-5 μM; 24 h) decreases the cellular amount of DNMT1 in a dose-dependent manner in MDA-MB-231[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549, SW1573 cells
-
Concentration:11.7, 21 µM
-
Incubation Time:48 h
-
Result:Showed antiproliferative activity in A549 (63.7% cell growth), SW1573 cells (59% cell growth).
-
Cell Line:A549, SW1573 NSCLC cells
-
Concentration:5 µM for A549 cells, 10 µM for SW1573 cells
-
Incubation Time:4 days
-
Result:Induced cell cycle arrest at S phase and apoptosis.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (human colon carcinoma HCT116 xenograft model)[3]
-
Dosage:2, 10 mg/kg
-
Administration:I.p.; three times per week for five weeks
-
Result:Caused significant inhibition of tumor growth at the doses of 2 and 10 mg/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 865838-26-2
-
Appearance Solid
-
Molecular Weight 257.22
-
Formula C10H12FN3O4
-
Color White to off-white
-
SMILES
O=C1N([C@@H]2C(F)=C(CO)[C@@H](O)[C@H]2O)C=CC(N)=N1
-
Synonyms
TV-1360; Fluorocyclopentenylcytosine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
bioRxiv
2023 Jan 10:2023.01.09.523344. PMID: 36711674
Solvent & Solubility
In Vitro:
DMSO : ≥ 50 mg/mL (194.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sarkisjan D, et al. The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2. PLoS One. 2016 Sep 9;11(9):e0162901. [Content Brief]
[2]. Balboni B, et al. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. [Content Brief]
[3]. Fahy J, et al. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012 Dec;22(12):1427-42. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8877 mL | 19.4386 mL | 38.8772 mL | 97.1931 mL |
| 5 mM | 0.7775 mL | 3.8877 mL | 7.7754 mL | 19.4386 mL | |
| 10 mM | 0.3888 mL | 1.9439 mL | 3.8877 mL | 9.7193 mL | |
| 15 mM | 0.2592 mL | 1.2959 mL | 2.5918 mL | 6.4795 mL | |
| 20 mM | 0.1944 mL | 0.9719 mL | 1.9439 mL | 4.8597 mL | |
| 25 mM | 0.1555 mL | 0.7775 mL | 1.5551 mL | 3.8877 mL | |
| 30 mM | 0.1296 mL | 0.6480 mL | 1.2959 mL | 3.2398 mL | |
| 40 mM | 0.0972 mL | 0.4860 mL | 0.9719 mL | 2.4298 mL | |
| 50 mM | 0.0778 mL | 0.3888 mL | 0.7775 mL | 1.9439 mL | |
| 60 mM | 0.0648 mL | 0.3240 mL | 0.6480 mL | 1.6199 mL | |
| 80 mM | 0.0486 mL | 0.2430 mL | 0.4860 mL | 1.2149 mL | |
| 100 mM | 0.0389 mL | 0.1944 mL | 0.3888 mL | 0.9719 mL |